Abstract
Background: T-cell lymphomas are a heterogeneous group of non-Hodgkin's lymphomas (NHLs). With the exception of anaplastic lymphoma kinase protein-positive large-cell lymphoma, standard chemotherapy provides dismal long-term outcomes when compared with NHLs with B-cell immunophenotype. Design: We review the literature on the role of high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) in T-cell NHLs both as up-front treatment and in the salvage setting. The role of allogeneic transplantation will also be reviewed. Results: Results from five prospective, nonrandomized and six retrospective studies evaluating the role of HDT and ASCT in the up-front setting show that patients in first complete or partial remission especially those who present with advanced disease and high prognostic index of peripheral T-cell lymphoma score may benefit from this approach. In the relapsed and/or refractory setting, most series show results that are comparable with those seen in patients with B-cell lymphomas if transplanted with chemosensitive disease. There is limited evidence to suggest that an immunemediated graft-versus-lymphoma effect may result in long-term disease remissions in some patients after allogeneic transplantation. Conclusions: Randomized studies comparing HDT and ASCT with conventional chemotherapy are needed in T-cell lymphomas.
Original language | English (US) |
---|---|
Pages (from-to) | 1471-1477 |
Number of pages | 7 |
Journal | Annals of Oncology |
Volume | 22 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2011 |
Keywords
- Review
- Stem-cell transplantation
- T-cell non-Hodgkin's lymphoma
ASJC Scopus subject areas
- Hematology
- Oncology